Abyx
Provides an AI-driven platform for immunogenicity and trial-risk assessment for biologics. The platform ingests sequence and assay data, enriches datasets (including privacy-preserving synthetic augmentations), predicts HLA-aware immunogenicity and downstream pharmacokinetics, and produces explainable, calibrated outputs and traceable decision packs intended to support clinical and regulatory planning.
Industries
biotechnology
pharmaceutical
Nr. of Employees
small (1-50)
Services
Platform workflow that ingests sequence and assay data, enriches datasets, predicts HLA-aware immunogenicity and downstream PK implications, and produces explainable, calibrated decision packs to support experimental planning and regulatory review.
Platform workflow that ingests sequence and assay data, enriches datasets, predicts HLA-aware immunogenicity and downstream PK implications, and produces explainable, calibrated decision packs to support experimental planning and regulatory review.
Expertise Areas
- Immunogenicity modeling
- Translational PK/PD prediction
- AI/ML for biologics
- Explainable AI for regulated settings
Key Technologies
- Sequence analysis (FASTA)
- HLA typing and coverage analysis
- Machine learning models for immunogenicity
- Explainable AI (XAI)